Doximity Shares Decline Amidst AI Disruption Concerns
Money

Doximity Shares Decline Amidst AI Disruption Concerns

authorBy Mr. Money Mustache
DateApr 13, 2026
Read Time3 min

In the first quarter of 2026, ClearBridge Investments' Mid Cap Strategy observed significant market dynamics, where mid-cap stocks demonstrated robust performance, outstripping both large and small-cap equities. However, amidst this backdrop, Doximity (NYSE:DOCS), a digital platform tailored for medical professionals, experienced a notable downturn. This decline was primarily fueled by investor apprehension regarding the potential for artificial intelligence (AI) to disrupt the pharmaceutical development and advertising sectors. Despite these short-term concerns, ClearBridge, while divesting from some positions, has chosen to retain a minor stake in Doximity, signaling a belief in the company's competitive standing and its prospective long-term advantages from AI integration.

ClearBridge Investments, a prominent global equity manager, recently released its commentary for the first quarter of 2026, focusing on its Mid Cap Strategy. The report highlighted the strong showing of mid-cap stocks during this period, with the Russell Midcap Index registering a 1.3% increase. This performance notably surpassed that of large-cap equities, which saw a 4.2% decrease, and small-caps, which recorded a modest 0.9% rise. This trend indicated a broadening of market leadership, shifting away from a singular focus on large-cap growth.

Despite the overall positive trend for mid-cap stocks, investor concerns, partly influenced by geopolitical events such as the US-Israel-Iran conflict, also played a role. However, the performance of these stocks was largely tethered to individual company fundamentals and prevailing sector trends. Within this environment, the ClearBridge Mid Cap Strategy itself underperformed its benchmark, a result attributed to challenges encountered in the information technology, healthcare, and consumer discretionary sectors. The strategy's emphasis on consumer discretionary firms underscores its adaptive approach to selecting companies capable of thriving across diverse economic conditions.

A specific area of weakness for the strategy in the first quarter was the healthcare sector, with Doximity, Inc. (NYSE:DOCS) being a significant detractor. Headquartered in San Francisco, Doximity operates a cloud-based digital platform serving medical professionals. As of April 10, 2026, Doximity's stock closed at $21.05 per share, having experienced a -14.40% return over the preceding month and a substantial 59.98% loss in value over the last three months, bringing its market capitalization to $3.96 billion.

ClearBridge's Q1 2026 investor letter explicitly noted Doximity's struggles, attributing them to investor anxieties over AI's potential to disrupt drug development and advertising. While ClearBridge decided to exit its position in ICON, another firm impacted by similar concerns, it opted to maintain a smaller holding in Doximity. This decision is rooted in the conviction that Doximity possesses a strong competitive position and, despite immediate disruption fears, is poised to emerge as a significant beneficiary of AI advancements in the long run.

Doximity was not listed among the 40 most popular stocks favored by hedge funds entering 2026. Data indicates that 51 hedge fund portfolios held Doximity at the close of the fourth quarter, an increase from 44 in the previous quarter. In the third quarter of fiscal year 2026, Doximity reported revenues of $185 million, marking a 10% year-over-year increase and exceeding guidance by 2%. Although acknowledging Doximity's investment potential, the analysis suggests that other AI-related stocks might offer more significant upside with reduced downside risk, particularly those benefiting from ongoing economic trends and policies.

In summary, Doximity's recent stock performance reflects a market grappling with the rapid advancements and disruptive potential of AI, particularly within specialized sectors like healthcare. The decision by ClearBridge Investments to retain a position, albeit reduced, underscores a nuanced perspective: while immediate challenges are evident, the long-term strategic advantages and integration of AI could ultimately bolster Doximity's market standing. This situation highlights the complex interplay between technological innovation, investor sentiment, and strategic investment choices in a dynamic market landscape.

More Articles
Money
Analyzing the Sustainability of REM's High Dividend Yield
This article delves into the sustainability of the iShares Mortgage Real Estate ETF (REM)'s impressive 9.55% dividend yield, focusing on its core holdings. It examines how major mortgage REITs like Annaly Capital Management and AGNC Investment Corp. contribute to the ETF's income stability, while also highlighting potential vulnerabilities, particularly with Blackstone Mortgage Trust. The analysis considers recent financial performances, dividend coverage, and market conditions impacting the fund's overall yield durability.
By Vicki RobinApr 13, 2026
Money
Strategy Firm Acquires $1 Billion in Bitcoin Through Preferred Stock Offering
Strategy, a leading cryptocurrency acquisition firm, recently purchased 13,927 Bitcoin valued at approximately $1 billion USD. This significant acquisition was entirely financed through the issuance of the company's preferred stock, named Stretch. This move highlights Strategy's ongoing commitment to expanding its Bitcoin holdings, leveraging its financial instruments to support its digital asset strategy.
By Mr. Money MustacheApr 13, 2026
Money
GM's Resilience Amidst Automotive Industry Headwinds
Despite a challenging automotive market marked by declining sales, elevated interest rates, and geopolitical uncertainties, a leading analyst maintains a 'Buy' rating on General Motors (GM). The company's robust financial health, efficient cost structure, diversified product portfolio, and strategic capital returns position it favorably to navigate economic downturns, building on a strong performance in the previous year where it led US auto sales and achieved significant operating profits.
By Scott PapeApr 13, 2026
Money
Index ETFs Versus Individual Stocks: A Prudent Investment Choice
Many investors often wonder whether to invest in individual stocks or broad market index ETFs. While individual stocks might offer a chance for significant gains, they come with higher risks. This article explores the advantages of investing in index ETFs like Vanguard S&P 500 ETF and Vanguard Total Stock Market ETF, highlighting how they offer diversified exposure and often outperform active managers. We delve into expert opinions, including Warren Buffett's advice, to provide a clear perspective on this investment dilemma.
By Mr. Money MustacheApr 13, 2026
Money
ImmunityBio Reports Robust Q1 Preliminary Sales and ANKTIVA's Global Expansion
ImmunityBio Inc. (IBRX) announced strong preliminary Q1 2026 net product revenue of approximately $44.2 million, surpassing analyst expectations. The success is primarily attributed to its flagship therapy, ANKTIVA, which has secured regulatory approvals in five regions globally. The company also confirmed the completion of enrollment for a key clinical study and outlined measures to enhance regulatory compliance following recent communications with the FDA.
By Dave RamseyApr 13, 2026